Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1 by Beneke, Sascha et al.
Published online 3 October 2008 Nucleic Acids Research, 2008, Vol. 36, No. 19 6309–6317
doi:10.1093/nar/gkn615
Rapid regulation of telomere length is mediated by
poly(ADP-ribose) polymerase-1
Sascha Beneke
1,2, , Odile Cohausz
3, Maria Malanga
3,4, Petra Boukamp
2,
Felix Althaus
3 and Alexander Bu ¨rkle
1
1Molecular Toxicology Group, Department of Biology, University of Konstanz, 78457 Konstanz, Germany,
2Department Genetics of Skin Carcinogenesis, German Cancer Research Center, Im Neuenheimer Feld 280, 69120
Heidelberg, Germany,
3Institute of Veterinary Pharmacology and Toxicology, University of Zurich/Vetsuisse faculty,
Winterthurerstrasse 260, 8057 Zurich, Switzerland and
4Department of Structural and Functional Biology,
University Federico II of Naples, Via Cinthia, Monte S. Angelo, 80126 Naples, Italy
Received June 30, 2008; Revised August 25, 2008; Accepted September 10, 2008
ABSTRACT
Shelterin/telosome is a multi-protein complex at
mammalian telomeres, anchored to the double-
stranded region by the telomeric-repeat binding fac-
tors-1 and -2. In vitro modification of these proteins
by poly(ADP-ribosyl)ation through poly(ADP-ribose)
polymerases-5 (tankyrases) and -1/-2, respectively,
impairs binding. Thereafter, at least telomeric-
repeat binding factor-1 is degraded by the protea-
some. We show that pharmacological inhibition of
poly(ADP-ribose) polymerase activity in cells from
two different species leads to rapid decrease in
median telomere length and stabilization at a lower
setting. Specific knockdown of poly(ADP-ribose)
polymerase-1 by RNA interference had the same
effect. The length of the single-stranded telomeric
overhang as well as telomerase activity were not
affected. Release of inhibition led to a fast re-gain
in telomere length to control levels in cells
expressing active telomerase. We conclude that
poly(ADP-ribose) polymerase-1 activity and prob-
ably its interplay with telomeric-repeat binding
factor-2 is an important determinant in telomere
regulation. Our findings reinforce the link between
poly(ADP-ribosyl)ation and aging/longevity and also
impact on the use of poly(ADP-ribose) polymerase
inhibitors in tumor therapy.
INTRODUCTION
Telomeres are structures at the end of chromosomes,
which comprise a highly repetitive DNA sequence
(T2AG3 in vertebrates) and a protective, speciﬁc protein
complex (shelterin/telosome) with associated nontelo-
mere-speciﬁc proteins (1,2). The telomeric G-rich strand
runs from the centromere outwards and ends in a single-
stranded 30-overhang (3). Telomeres shield chromosomal
ends from degradation and undesirable repair activities, at
least partially, by t-loop formation, with the 30-overhang
folding back and invading the double-stranded DNA (4).
Shelterin can be divided into three subcomplexes: (i) a
telomere-length regulation complex, comprising telomeric
repeat-binding factor 1 (TRF1) bound to the double-
stranded region and associated proteins; (ii) a telomere/
t-loop stabilizing complex, comprising TRF2 bound to the
double strand and associated proteins; and (iii) the single-
strand binding protein POT1, associated with the TRF1
subcomplex via TPP1. The protein TIN2 interconnects the
two double-strand binding complexes. Binding of TRFs to
telomeres is postulated to be under control of the activity
of poly(ADP-ribose) polymerases (PARPs): TRF1 inter-
acts with PARP5 (tankyrases, TNKS) (5,6) and TRF2
with PARP1 and PARP2 (7–9). Poly(ADP-ribosyl)ation
is a complex posttranslational protein modiﬁcation and
represents an immediate response of cells to genotoxic
stress, due to the dramatic activation of PARP1 and
PARP2 by DNA strand breaks. PARPs use NAD
+ as
substrate and synthesize a branched polymer of ADP-
ribose units, with stoichiometric release of nicotinamide
(10). Apart from undergoing covalent modiﬁcation with
poly(ADP-ribose) (PAR), proteins may also bind PAR in
a noncovalent yet speciﬁc manner (11). Whereas covalent
modiﬁcation of a target protein renders it mostly inactive,
noncovalent binding to PAR can have diverse eﬀects,
leading either to stimulation or repression of activity,
probably also dependent on PAR chain length and
branching frequency (11–14). The main target proteins
undergoing poly(ADP-ribosyl)ation are PARPs them-
selves, thus creating an autoregulatory feedback loop,
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in vitro, e.g. histones H1 and H2B, p53, XPA, HMG2,
CenpA, DNA-PKcs, topoisomerase-1 and transcription
factors such as YY1 (15,16). PARP1 is the founding
member of a large family of PARPs (17). The dramatic
PAR formation stimulated by genotoxic agents has been
associated with PARP1 and PARP2, with PARP1 being
the most active protein, responsible for about 90% of
cellular PAR formation observed under these conditions
(18). Overall, PARP activity has been implicated in nearly
all aspects of genome integrity and cell survival regulation,
like repair (19,20), transcription (21–25), DNA replication
(26–28), diﬀerentiation (26,29,30), mitosis and mitotic
organization (31–35), choice of cell death pathway
(36,37), vesicle traﬃcking (38) and telomere-length regula-
tion (6,39). Furthermore, we have shown that the level of
PARP activity induced by DNA strand breaks in mono-
nuclear blood cells correlates with mammalian life span
(40) and that enzymatic activity of recombinant puriﬁed
human PARP1 is 2-fold higher than that of the rat protein
(41,42). Thus, the PAR system seems also to be involved
in cellular/organismal aging, as is the case for several other
repair enzymes (i.e. WRN, BLM and ATM).
Controversial results have been published regarding the
inﬂuence of Parp1 knockout on telomere length in mice.
Whereas one group showed no impact (43,44), others
reported shortened telomeres (45,46).
Overexpression of NLS-tagged TNKS1 leads to telo-
mere elongation (39), whereas knockdown by siRNA
leads to mitotic arrest and cell death (32), apparently by
interfering with spindle organization and telomere-speciﬁc
cohesion cleavage (47–49). Intriguingly, inhibitors of
PARP activity do not have an impact on cell survival,
although they are eﬀective against TNKS1 in vitro (50).
Thus, TNKS may not be aﬀected within a cell at inhibitor
concentrations used to block PARP1 and PARP2 activity.
To clarify the role of PARPs on telomere regulation, we
used cells from two mammalian species (hamster and
human) and inhibited PARP activity either pharmacolo-
gically or more selectively by siRNA against PARP1 or
PARP2.
MATERIALS AND METHODS
Cellculture andtreatment
Cells were grown in DMEM supplemented with 100U/ml
of penicillin and 0.1mg/ml streptomycin and 10% FCS, at
378C, 95% humidity and 5% CO2. Cells were counted and
seeded 3h before addition of 3-aminobenzamide (3AB) or
including the inhibitor in subsequent passages. 3AB was
dissolved in medium without FCS and sterile ﬁltered.
Chromosome isolationfor quantitative fluorescence
insitu hybridization
COM3 hamster cells. This cell system has been described
before (51,52). Cells in 75cm
2 ﬂasks were treated with
0.01mg/ml colcemide (Life Technologies/Invitrogen
GmbH, Germany) for 1h to stall mitosis. Then, the super-
natant was removed and replaced with 4ml of chromo-
some isolation buﬀer (CIB; 0.5mMCaCl2, 1mMMgCl2,
25mM Tris–HCl, 750mM hexane-diol, pH 7.5; 1% acetic
acid added before use). The supernatant was replaced with
new CIB and mitotic cells were shaken oﬀ the ﬂask by
gentle rinsing. Both CIB supernatants were pooled, cells
were spun down for 10min at 200g and the resulting pellet
was resuspended in methanol+acetic acid (3+1). Fixed
cells were stored at –208C.
Human cells (HeLaS3, IMR90). Cells were treated with
0.01mg/ml colcemide (Life Technologies) for 1h to stall
mitoses. Adherent cells were harvested by trypsin (Life
Technologies) treatment for 5min at room temperature
and washed 1  with PBS. Fixation was essentially done
as described in (53). Fixed cells were stored at –208C.
Quantitative fluorescence insitu hybridization
analysis and evaluation
Quantitative ﬂuorescence in situ hybridization (Q-FISH)
analysis was done essentially as described (54). Metaphase
spreads on Superfrost slides (VWR, Germany) were hybri-
dized to Cy3-labeled PNA-telomere probes (Dako
Cytomation, Denmark), counterstained with DAPI and
analyzed with a ﬂuorescence microscope (Zeiss Axiovert)
using Axiovision software (Zeiss, Germany). Telomere
signal intensities were analyzed with TeloQuant (Dako
Cytomation). For any single data point the median of
signal intensities of telomeres from at least 500 chromo-
somes was determined. Each experiment was performed in
triplicates. Data are expressed as percent of control.
Telomeric-repeat-amplifying-protocol assay
Telomeric-repeat-amplifying-protocol (TRAP) assay was
done according to the manufacturer’s instructions
(Intergen, TRAPeze telomerase detection kit). X-ray
ﬁlms were scanned and analyzed by using ImageQuant.
Calculation of total product generated (TPG) units was
done according to the manufacturer’s instructions
(Intergen, NY, USA TRAPeze telomerase detection kit).
Telomere oligo-ligation assay
Telomere oligo-ligation assay (T-OLA) was performed
essentially as described (55). Brieﬂy, 5mg of genomic
DNA was either treated with mung-bean exonuclease or
left untreated. After phenol–chloroform puriﬁcation and
precipitation, DNA was hybridized to
32P end-labeled oli-
gonucleotides (T2AG3)3 or (A2TC3)3 overnight at 508C
followed by 5h incubation at 508C with Taq-ligase
(NEB, Germany) in Taq-ligase buﬀer. DNA was extracted
by phenol–chloroform puriﬁcation and precipitated, and
ligation products were resolved on 5% polyacrylamide/
6M urea gels. DNA was blotted onto HybondN+ mem-
branes (GE HealthCare, Europe, Germany) and exposed
to X-ray ﬁlms (Kodak). Scans from autoradiographs were
analyzed by using ImageQuant software (GE Healthcare).
The percentage of intensity of each band (relative to total
lane intensity) was calculated and normalized to the length
of ligation products. As we routinely detected ligation to
quadruplicates also in negative controls, products of less
than 5  (A2TC3)3 were excluded from the analysis.
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Small interfering RNAs (siRNAs) were synthesized in vitro
from oligonucleotide templates (Microsynth, Switzerland)
using a siRNA construction kit (Ambion, TX, USA),
according to the manufacturer’s instructions. The 21-nt
sequences in the human coding region of PARP-1
and PARP-2 cDNA were chosen as targets for siRNA. A
scrambled version of siRNA PARP-1 sequence was used as
a negative control. Transfection procedure and siRNA
sequences are described in ref. (56), except for siRNA
P1n (2310–2329): CAUCGAGGUGGCCUACAGU.
Statistical analyses
Experiments were performed independently at least three
times. Statistical analysis was done by using Prism5 or
Instat3 (GraphPad Software). One-way or repeated mea-
sures ANOVA was used for calculation of signiﬁcance if
not stated otherwise. Error bars represent means SEM if
not stated otherwise.
RESULTS
Dose-dependent telomere shortening by 3AB treatment
Binding of TRF proteins to the telomeric double strand
are, at least in the case of TRF1, under control of PARP5
(TNKS) activity (5,6), leading to TRF1 degradation (57).
Telomere elongation by overexpression of an artiﬁcially
NLS-tagged version of TNKS1 is a rather slow process
(39). TRF2 has been shown to interact with two other
PARPs involved in DNA repair, namely PARP1 (7) and
PARP2 (8). But the latter one was detected only in ALT
(alternative lengthening of telomeres) cells, which use
homologous recombination to maintain their telomeric
DNA. So far, the impact of PARP activity on TRF2 sub-
strate binding and telomere regulation remains elusive,
although a recent publication reported the presence of
PARP1at eroded telomeres (9).
Inordertotesttheshort-termresponsivenessoftelomere
regulation in mammalian cells to treatment with the pan-
PARP inhibitor 3AB, we exposed the cells to various con-
centrations for 1 week and analyzed median telomere
length by Q-FISH. Telomere signal intensity reduction
was clearly correlated to 3AB concentration (Figure 1),
leveling out at 75% of controls at the highest concentra-
tion applied (4mM). The cell lines used in this study have
asimilartelomerelengthof 5kbasmeasuredbySouthern
blotting (5.5kb HeLaS3, human) and comparison of Q-
FISH signals with known standards (5kb COM3, hamster)
(data not shown). Cell numbers and cell death rates were
not signiﬁcantly aﬀected, except for a minor increase in
proliferation time in cells treated with highest dose of
3AB in long-term experiments (Supplementary Figure 1A
and B). This indicates that the eﬀect is not dependent
on interference with cell cycle progression or cell viability,
in line with the fact that mono-ADP-ribosyl transferases
involved in signaling cascades are not inhibited at the 3AB
concentrations used (58). Therefore, the dose–
response curves observed can be attributed to gradual
inhibition of overall PARP activity.
Time course of 3AB-inducedtelomere shortening
Next, we studied the kinetics of telomere shortening
induced by the PARP inhibitor. We wanted to address if
long-term treatment with 3AB would lead to a steady
decrease in telomere length and subsequent cell death or
senescence, which is induced by critically short telomeres
(59). Therefore, we treated cells continuously with 3AB.
After the ﬁrst week, treated cultures were split and one
half was further inhibited, whereas the other half was
released, and both were cultured for 3 additional weeks
(Figure 2). In HeLaS3 and COM3 cells, we detected a
Figure 2. Time course of telomere shortening during 3AB treatment.
Telomere length was measured and plotted as in Figure 1. HeLaS3 and
COM3 cells were treated with 2mM and 4mM 3AB, respectively. After
156h incubation with the inhibitor, cultures were split and one
part was released, whereas the other was further incubated with 3AB.
3AB  indicates cultures released from the inhibitor. After an initial
drop, telomeres are stabilizing at a new lower level. Release leads to
fast increase in median length, which stabilizes at control levels. Red
diamonds, HeLaS3/3AB; dark blue triangles, COM3/3AB; orange
circles, HeLaS3 released; light blue squares, COM3 released.
 P<0.05,
  P<0.01, compared to control. #P<0.05 released
compared to treated cultures; unpaired two-tailed t-test.
Figure 1. Dose-dependent telomere shortening in mammalian cells
exposed to increasing concentrations of 3AB. Telomere length was
measured by Q-FISH and resulting values were expressed as percentage
of the corresponding control. HeLaS3 and COM3 hamster cells were
treated with concentrations of 3AB as indicated for 1 week. Both show
a dose-dependent decrease in telomere signal intensity, with  85% and
75% of control level, respectively, at the highest concentration of the
inhibitor. Squares, HeLaS3; triangles, COM3;
 P<0.05,
  P<0.01,
compared to control.
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doubling (PD) within 48h. This eﬀect cannot be explained
bythemereinhibitionoftelomeraseactivity,astelomerase-
negativeﬁbroblastsshowamaximaldecreaseof50–200bp/
PD (60). Telomeres of long-term treated cultures stabilized
at about 70 and 80% of control levels in hamster and
human cells, respectively. HeLaS3 showed less pronounced
telomere shortening, because the impact of 3AB treatment
is dose-dependent and we used only 2mM of 3AB as a
maximal concentration for this cell line. Upon release
from 3AB, telomeres were rapidly elongated to and stabi-
lized at control levels. The speed of increase was nearly
identical in hamster and in human cells with about 15%
addition/PD. Interestingly, HeLa cells showed an over-
shooting reaction and elongated to a median of 110% of
control telomeres, compared to 100% control length in
COM3. Thereafter, HeLaS3 telomeres shortened again
and control levels were re-established. Re-elongation was
not detectable in IMR90 lung ﬁbroblasts lacking active
telomerase (Figure 3). Southern blotting of digested geno-
mic DNA (from 204h and 684h postinitial treatment)
and probing with a G-strand-speciﬁc oligonucleotide sup-
ported the Q-FISH data, which were obtained by using
PNA probes, although diﬀerences were less pronounced
and did not reach signiﬁcance (Supplementary Figure 2A
and B). The 30-overhang at the time of highest divergence
between treated and released cultures (204h) was not
altered, as assessed by the T-OLA method (Figure 4).
Telomerase activity measured by the PCR-based TRAP
method (Figure 5A and B) was not aﬀected either, as
there were no signiﬁcant diﬀerences between the diﬀerently
treated cultures after 4 weeks (control versus 3AB-treated
versus 3AB-released). Thus, in our hands, PARP inhibitors
did not downregulate telomerase activity in vitro, although
opposite ﬁndings have been published by one group, using
the same method (61,62).
PARP1isresponsiblefortelomereshorteninginducedby3AB
Knockdown of TNKS1 by siRNA approach led to mitotic
failure (32,47,49) and it has been shown in vitro that
TNKS1 is equally sensitive to inhibition as PARP1 (50).
But as 3AB has been routinely used for continuous treat-
ment of cells without any impact on cell viability, the
situation in a cellular context may be diﬀerent (see
Discussion section). As PARP1 as well as PARP2 localize
to telomeres by interaction with TRF2 (7,8), we wanted to
determine which of these two PARPs is responsible for the
observed 3AB eﬀect on telomeres.
Therefore, we transfected HeLaS3 cells with siRNAs
speciﬁcally targeting either PARP1 (P1) or PARP2 (P2).
We also cotransfected both siRNAs in a 1:1 ratio, keeping
the total siRNA concentration constant. The eﬃcacy of
siRNA-induced knockdown is shown in Supplementary
Figure 3A for PARP1 and Supplementary Figure 3B for
PARP2. On average, PARP1 protein was knocked down
slightly more eﬀectively than PARP2, with residual levels
of 17% versus 11% at 24h posttransfection; 9% versus
29% at 72h posttransfection; and 37% versus 75% at
144h posttransfection. In double transfectants, PARP1
knockdown was only half as pronounced as in single
Figure 4. 3AB does not inﬂuence telomeric 30-overhang. The length of the telomeric 30-overhang was determined in HeLaS3 cells by using the T-OLA
method at 204h of 3AB treatment (greatest diﬀerence between treated and released cultures). Bars represent percentage of intensity of bands in one
lane. Intensities were normalized to the number of ligated oligonucleotides. There is no signiﬁcant diﬀerence between 3AB treated, released and
control cells. Gray bars, controls; open bars, 2mM 3AB; black bars, released.
Figure 3. Irreversible telomere shortening in IMR90 ﬁbroblasts exposed
to the PARP inhibitor 3AB. IMR90 ﬁbroblastswere incubated with
3AB for 14 days and released thereafter. After 14 days, signiﬁcant
telomere shortening is seen in IMR90 cells treated with 4mM 3AB.
After 21 days, all cultures show signiﬁcant telomere shortening com-
pared to telomeres from control cells. The arrow marks the time of
release from 3AB. Triangles/dashed line, 1mM 3AB; circles/closed line,
2mM 3AB; diamonds/dotted line, 4mM 3AB;
 P<0.05,
  P<0.01
compared to control.
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same knockdown levels (11%, 13% and 67%).
Therefore, PARP1 siRNA was needed in the highest con-
centration for an eﬀective knockdown. We monitored
telomere length by Q-FISH and normalized the signal
intensities to untreated controls (Figure 6A). As expected,
transfection of a scrambled version of P1 (Scr) did
not show any signiﬁcant eﬀect, whereas 3mM 3AB
induced a fast drop in PNA-dependent ﬂuorescence
within the ﬁrst 48h. Later, telomeres stabilized at a
new length as in previous experiments. P1 siRNA also
induced telomere shortening with delayed kinetics,
probably because PARP1 protein had to be degraded to
abrogate activity. Starting from 72h posttransfection,
there was no signiﬁcant diﬀerence between the 3AB trea-
ted and with P1 siRNA transfected cells with regard
to telomere length. Transfection of siRNA P2
showed no impact on PNA ﬂuorescence compared to
Scr siRNA or untreated controls. Double tranfectants
(P1+2) showed an intermediate decrease in telomere
length at later time points, further strengthening the
hypothesis that only inhibition of PARP1 activity is
responsible for telomere shortening. To demonstrate that
PARP1 is indeed the only eﬀector of 3AB treatment and
to exclude oﬀ-target eﬀects of the siRNA, we treated P1
siRNA transfected cells simultaneously with 3AB and we
tested a second PARP1 siRNA (P1n) at two
time points where 3AB mediated telomere shortening
was diﬀerent (48h) and identical (144h) to P1 siRNA
(Figure 6B). Silencing eﬃciency mediated by P1n was
similar to P1 (data not shown). Both siRNAs showed
near-identical impact on telomere shortening and double
treatment with P1 and 3AB was indistinguishable from
3AB administration alone. With these experiments
we demonstrate that PARP1 and not PARP2 is responsi-
ble for the observed negative eﬀect of 3AB on telomere
length.
DISCUSSION
We found in two mammalian cell systems (hamster and
human) that pharmacological inhibition of PARP1 led to
a fast, dose-dependent decrease of telomere length
(Figures 1 and 2). After release from the inhibitor 3AB,
telomeres elongated back to control levels in telomerase-
expressing cells (Figure 2), whereas they stayed short in
telomerase-negative cells (Figure 3). The inhibitor neither
inﬂuenced the telomeric 30-overhang length (Figure 4) nor
telomerase activity in a standard TRAP assay (Figure 5),
in line with published data (45). In order to discriminate
between the two diﬀerent PARPs (PARP1 and PARP2)
proposed to interact with TRF2 and sensitive to the used
inhibitor concentration, we analyzed telomere length after
knockdown of each by siRNA (Figure 6). Surprisingly,
only cells transfected with PARP1 siRNA showed telo-
mere shortening. Two independent PARP1 siRNAs pro-
duced the same eﬀect. Furthermore, PARP1 knockdown
reproduced perfectly the results with 3AB, and the eﬀect
of combination of both was identical to inhibitor treat-
ment alone. These results strongly suggest that PARP1
is the only eﬀector protein responsive to a standard
PARP inhibitor that mediates telomere regulation,
although we cannot exclude that other PARP family mem-
bers—with the exception of PARP2—may contribute to a
minor extent to this eﬀect.
In 2004, Dynek and colleagues (32) published that
knockdown of TNKS1 leads to mitotic failure. Several
recent publications link TNKS1 with spindle formation/
regulation and mitosis progression (47–49). In vitro experi-
ments revealed that TNKS1 and PARP1 are equally sen-
sitive to inhibition by diﬀerent drugs (50). But 3AB has
been widely used without any detectable inﬂuence on cell
cycle progression or cell viability (including this work).
Thus, most likely, TNKS1 is not inhibited in cells by the
drug concentrations used. Supporting this notion, cellular
PARP1 activity has been reported to be fully inhibited at a
Figure 5. 3AB does not aﬀect in vitro telomerase activity. After 4 weeks of incubation of cells, in vitro telomerase activity of COM3 cell extracts were
measured by conventional PCR-based assay (TRAP). (A) Representative gel with TRAP products; 3AB+ and 3AB  lanes were from the same gel
and only rearranged to the control lane. 3AB+, continuously 3AB treated; 3AB , 3 weeks after 3AB release; C, control cells; St, standard reaction
for normalization; C RNAse, control sample treated with RNaseA; C Heat, control sample treated with heat; LB, lysis buﬀer only; St Heat, standard
reaction treated with heat. (B) Evaluation of three independent experiments. The activity is expressed as total product generated (TPG) units. No
signiﬁcant diﬀerences were observed. Hatched bar, control; black bar, 4mM 3AB; open bar, released.
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whereas TNKS1 was only completely blocked at concen-
trations greater 40mM (64). Additionally, TNKS-
mediated telomere elongation is slow (signiﬁcant only
after several PD) and only achieved by overexpression of
an NLS-tagged version, as otherwise the protein is not
found in the nucleus after transfection (39,65).
Therefore, we reasoned that the eﬀect of 3AB in our
experimental setup is probably not dependent on
TNKS1, but on other PARPs localized at telomeres.
Good candidates were PARP1 and PARP2, which have
been shown to interact only with TRF2 within the shel-
terin complex (7–9).
We provide evidence that treatment of intact mamma-
lian cells with the well-established PARP inhibitor 3AB
leads to a reversible loss of telomere length, shown by
Q-FISH (Figures 1–3) as well as by Southern blotting
(Supplementary Figure 2). Southern blotting is a less sen-
sitive method compared to Q-FISH, as subtelomeric
regions, which can be of substantial size [3kb, (66)] are
also includes in length determination.
The decline in telomere length was fast (about 30%
within 60h or 2.5 PD) and led to a new setting without
any obvious loss of cell viability. Both ﬁndings are per-
fectly in line with data published by d’Adda di Fagagna
and colleagues (45), who showed in embryonic ﬁbroblasts
from Parp1 knockout mice also 30% loss of telomere
length and a new stable setting. We demonstrated that
in hamster cells in vitro telomerase activity is not aﬀected
(Figure 5) and that the rate of telomere length decrease is
faster than expected from blocking telomerase alone.
Therefore, telomere loss must be due to incomplete repli-
cation or an active degradation process. Two nucleases
have been shown to localize to telomeres, i.e. the nucleo-
tide excision repair complex nuclease ERCC1/XPF (67) as
well as Apollo (68), a recently discovered ‘sibling’ of the
Artemis nuclease involved in nonhomologous end-joining.
Whether any of these are responsible for the observed
telomere shortening awaits further investigation. 3AB
treatement of telomerase-negative human ﬁbroblasts led
to accelerated telomere shortening compared to controls
(Figure 3). This also excludes telomerase as main eﬀector
of PARP inhibition, although two recent publications
described opposite ﬁndings using the same method
(61,62). Release from 3AB led to regain in telomeric
sequences with a similar rate as loss (1kb within 48h) in
telomerase expressing cells only. The sustained loss of
telomere length in IMR90 cells after release may well be
due to the fact that these ﬁbroblasts were close to senes-
cence. Inhibiting PARP at this critical point could desta-
bilize the telomeric structure and increase the
susceptibility to degradation processes, which may be
afterwards insensitive to re-established PARP activity.
In the literature, conﬂicting results have been reported
regarding the inﬂuence of PARP1 on telomere length reg-
ulation, based on two diﬀerent knockout mouse strains.
One group showed no impact on telomeres (43,44),
whereas the other reported shorter telomeres (45,46).
Treatment with pharmacological inhibitors has often
the disadvantage of interference with a whole enzyme
family, where speciﬁcity is needed for analysis of divergent
activities. Therefore, a RNA interference approach is the
best method to dissect in a short-term setting the inﬂuence
of proteins on speciﬁc regulatory processes.
To clarify the role of PARP1 and PARP2 in telomere
regulation, we used siRNA for both proteins. We showed
that only PARP1 and not PARP2 is involved in telomere
length regulation (Figure 6). Thus, regarding PARP1, we
conﬁrmed data from one of the knockout mouse models
(45), challenged by Samper et al. (43). The observed inter-
action of PARP2 with TRF2 in U2OS cells (8), which use
the ALT-recombination pathway to maintain telomeres,
may be conﬁned to this special case.
From our data, we propose the following
model: PARP1 interacts with TRF2at the telomere,
either (A) constantly throughout the cell cycle or (B)
only during a speciﬁc phase, e.g. S phase, when telo-
mere replication takes place and the t-loop structure has
Figure 6. Knockdown of PARP1 shortens telomeres similar to 3AB.
(A) HeLaS3 cells were transfected with diﬀerent siRNAs or incubated
with 3AB as telomere shortening control. Values were normalized to
untreated controls. 3AB treated cells show the same eﬀect as siRNA
against PARP1, whereas Scr and PARP2 siRNA have no eﬀect. Black
upside down triangles, 3AB treated; red diamonds, PARP1 siRNA
(P1); brown squares, PARP1+PARP2 siRNAs (P1+2); blue dots,
PARP2 siRNA (P2); gray triangles, scrambled siRNA (Scr);
 P<0.05,
  P<0.01 compared to control. (B) HeLaS3 cells were trea-
ted as in (A), but with a second unrelated PARP1 siRNA (P1n) and
double treated with P1 siRNA and 3mM 3AB (P1/3AB). Bar-code,
empty, control; light gray, Scr; orange, P1n; red, P1; blue, P1/3AB;
black, 3AB;
 P<0.01,
  P<0.001, compared to control.
6314 Nucleic Acids Research, 2008, Vol. 36, No. 19to be unfolded. In the ﬁrst case, PARP1 must be activated
at a certain time to fulﬁll its action on TRF2, in the latter
re-localization would bring PARP1 to its site of action. It
has been shown that TRFs slow down replication fork
progression on a telomeric template in vitro (69). Thus,
these proteins have to be dislodged in order to facilitate
proper telomere replication and maybe also for main-
tenance through telomerase by opening of the t-loop. In
model A, slowing down replication fork progression may
lead to unusual DNA structures or fork collapse, which
depend on PARP1 for re-activation (70). TRF2 is subse-
quently modiﬁed and replication can proceed. Many other
proteins and complexes involved in repair of stalled repli-
cation forks are also implicated in telomere regulation,
like the 911 complex (71), BLM and WRN (72), which
partially also interact directly with PARP1 (73–75).
Alternatively, it has been shown that PARP1 is a
member of the DNA replication complex and modiﬁes
several proteins therein (28). Thus, it is tempting to spec-
ulate that the replication fork carries its own ‘key’ for
opening the t-loop, i.e. PARP1. The replication complex
brings PARP1 to the telomere and the basal activity of
PARP1 leads to TRF2 modiﬁcation, t-loop opening and
replication fork passage. In this speculative model, no
DNA breaks or recombinogenic structural intermediates
are needed for activation of PARP1 towards TRF2, but
experimental proof awaits further investigations. Also, a
recent publication argues against a constant interaction of
PARP1 and TRF2 (9). If PARP1 is inhibited, telomeres
shorten to the point where the t-loop formation is still
possible and functions as a protective cap, but this struc-
ture would be instable (in the case of HeLaS3 and COM3
cells this would be 70% of initial telomere length). This
now enables the replication fork to displace the loosely
bound single-strand overhang just by passing by without
detaching TRF2. The ALT pathway is unlikely to be
involved in keeping telomeres stable at the new length
setting, as the hallmark of this mechanism, a broad
range of diﬀerent telomere lengths within a cell, could
not be detected.
We have previously shown that PARP activity in per-
meabilized PBMC stimulated by strand breaks correlates
positively with mammalian life span, but during organis-
mal aging, PARP activity declines (40). Many publications
show that PARP1 (and also PARP2) activity is not only
conﬁned to cellular response to genotoxic stress. In mam-
malian cells, PARP1 (and PAR) has also been shown to be
present at centromeres (76), centrioles (33,34) and telo-
meres (7). So far, inhibition of PARP activity in unstressed
cells showed eﬀects only in centriole regulation. Our pre-
sent data show that PARP1 activity also positively inﬂu-
ences telomere maintenance. Thus, during the aging
process, PARP1 activity may decline below a threshold,
where it is no longer able to maintain proper telomere
length. As PARP inhibition also leads to accelerated tel-
omere shortening in ﬁbroblasts, tissue regeneration from
somatic cells may be impaired as it reduces their prolifera-
tion capacity. Subsequently, telomere shortening during
compensatory enhanced tissue-renewal would deplete
replicating stem cells or their low-level telomerase
expressing progeny by senescence/apoptosis induction.
These two scenarios could lead ﬁnally to organ dysfunc-
tion and accelerated aging of the organism. It has already
been shown that tissues of aged individuals have a higher
number of senescent cells (77–79).
Our ﬁndings may also impact on a proposed combina-
tion therapy with genotoxic agents and PARP1 inhibitors
for tumor treatment. This approach has been shown to
increase the eﬃcacy of chemotherapeutics (80–83), but
with the new data presented here one should be cautious
about long-term eﬀects. Patients suﬀer sometimes from
secondary tumors induced by cytotoxic cancer treatment.
As the agents used also damage DNA in somatic, nonte-
lomerase expressing tissues, additional accelerated telo-
mere shortening by PARP1 inhibition may either induce
an earlier onset of senescence in these cells with the above
mentioned impact on organ aging or even trigger
enhanced genomic instability and support thus formation
of neoplasias.
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